Pharma BD Deal Intelligence
Novartis paid $1.0B upfront, the bulk of the $1.75B total, to acquire Mariana Oncology outright and bolt MC-339, an actinium-based radioligand therapy in small cell lung cancer, onto its Pluvicto and Lutathera franchise, though MC-339 itself was still preclinical at signing.
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Novartis agreed Thursday to acquire Mariana Oncology in a deal worth up to $1.75 billion, the latest move by the Swiss drugmaker to expand its radioligand…
Novartis is continuing its radiopharmaceutical roll with a $1.75 billion deal to buy Mariana Oncology. The acquisition adds MC-339, an…
Novartis has entered into an agreement to acquire Mariana Oncology for up to $1.75 billion, a move designed to strengthen its radioligand therapy pipeline.…
Source summaries from our enrichment pipeline; follow links for originals.
All 10 sources with sentiment breakdown →
Novartis acquired Mariana Oncology for $1.0B upfront plus up to $750M in milestones (total $1.75B), expanding its radioligand therapy (RLT) pipeline and infrastructure with MC-339 (an actinium-based RLT in small cell lung cancer) plus earlier RLT programs across solid tumors. Announced May 2, 2024, the all-cash acquisition completed in Q2 2024 and is reported as a completed business combination in Novartis's half-year 2024 financials (cash ~$1.1B net of cash acquired, plus contingent milestone consideration). The deal reinforces Novartis's leading radiopharmaceuticals position behind Pluvicto and Lutathera.
35K US cases/yr · $13.0B Global radiopharmaceutical market (2030 projected) · $1.4B Novartis Pluvicto 2024 net sales (PSMA RLT benchmark)
Small cell lung cancer (SCLC) accounts for approximately 13-15% of all lung cancer cases, with an estimated 30,000-35,000 new US cases annually and five-year survival below 7% for extensive-stage disease. Despite first-line platinum-etoposide plus atezolizumab or durvalumab (IMpower133, CASPIAN regimens), relapse is nearly universal within 6-12 months, creating acute unmet need in the second-line and beyond setting where tarlatamab (Imdelltra; Amgen DLL3 BiTE) now holds momentum after 2024 accelerated approval. Prostate cancer comprises approximately 300,000 new US cases annually with ~35,000 deaths; metastatic castration-resistant prostate cancer (mCRPC) represents the addressable population for PSMA-targeted radioligand therapies, where Novartis's Pluvicto (177Lu-PSMA-617) generated over $1.4B in 2024 sales. Breast cancer adds approximately 310,000 annual US cases. Mariana's lead asset MC-339 is an actinium-225-based radioligand targeting delta-like ligand 3 (DLL3), highly expressed in SCLC neuroendocrine cells. The alpha-emitting radioisotope actinium-225 delivers approximately 1,000-fold higher linear energy transfer than lutetium-177, with shorter tissue penetration (40-90 microns) enabling more selective tumor-cell killing. The broader solid tumor radiopharmaceutical market is projected to reach $13 billion by 2030, driven by Pluvicto expansion and next-generation assets.
Radioligand therapy (RLT) has emerged as one of oncology's most competitive growth segments. Novartis dominates with Pluvicto (lutetium Lu-177 vipivotide tetraxetan / 177Lu-PSMA-617) for mCRPC and Lutathera (lutetium Lu-177 dotatate) for gastroenteropancreatic NETs, contributing ~$2B combined 2024 revenue. Competing PSMA programs include Lantheus/Point Biopharma's PNT2002 (177Lu-PNT2002) and POINT-1-3 assets (now under Lantheus following 2024 acquisition), Bayer's 225Ac-PSMA-617 and Nubeqa (darolutamide) combinations, and Curium/Orano's 64Cu-PSMA imaging + therapy pairs. In DLL3-targeted SCLC, Amgen's tarlatamab (Imdelltra, DLL3xCD3 BiTE) gained accelerated approval May 2024 and is Mariana's most directly comparable competitor in mechanism-agnostic terms, with Phase 3 DeLLphi-304 ongoing. AstraZeneca/Fusion Pharmaceuticals ($2B deal March 2024, FPI-2059 actinium-225 NTSR1) and Eli Lilly/POINT Biopharma (now discontinued), Bristol-Myers Squibb/RayzeBio ($4.1B Dec 2023 for 225Ac-DOTATATE RYZ101) show Big Pharma RLT land-grab. Lead cold competitors in SCLC include topotecan, lurbinectedin (Zepzelca), and anti-PD-L1 combinations.
Acquisition completed in Q2 2024 (reported in Novartis's half-year 2024 financials as a completed business combination). Exact legal completion day not separately disclosed; dated to period end 2024-06-30.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Novartis AG / Mariana Oncology Inc. (this deal) | 2024 | $1.8B | — |
| Novartis AG / Advanced Accelerator Applications S.A. | 2017 | $3.9B | 98 |
| Novartis AG / Endocyte, Inc. | 2018 | $2.1B | 96 |
| Novartis AG / Lek Pharmaceuticals d.d. | 2002 | $876M | 88 |
| Novartis AG / GlaxoSmithKline plc | 2014 | $16.0B | 81 |
| Novartis AG / PTC Therapeutics Inc. | 2024 | $2.9B | 80 |
| Novartis AG / Chinook Therapeutics Inc. | 2023 | $3.5B | 78 |
← Browse all deals · How we score deals
More: 2024 deals · Novartis AG deals · Oncology deals